Crossmark

Evolution of antibody immunity to SARS-CoV-2

Crossref DOI link: https://doi.org/10.1038/s41586-021-03207-w

Published Online: 2021-01-18

Published Print: 2021-03-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gaebler, Christian http://orcid.org/0000-0001-7295-8128
Wang, Zijun

Lorenzi, Julio C. C. http://orcid.org/0000-0003-2492-3961
Muecksch, Frauke http://orcid.org/0000-0002-0132-5101
Finkin, Shlomo http://orcid.org/0000-0003-4474-2658
Tokuyama, Minami http://orcid.org/0000-0001-6488-9687
Cho, Alice

Jankovic, Mila

Schaefer-Babajew, Dennis http://orcid.org/0000-0002-5380-2950
Oliveira, Thiago Y.

Cipolla, Melissa

Viant, Charlotte

Barnes, Christopher O.

Bram, Yaron

Breton, Gaëlle

Hägglöf, Thomas

Mendoza, Pilar http://orcid.org/0000-0003-2957-1811
Hurley, Arlene

Turroja, Martina http://orcid.org/0000-0001-9640-0559
Gordon, Kristie

Millard, Katrina G. http://orcid.org/0000-0003-2247-3178
Ramos, Victor http://orcid.org/0000-0001-7353-3420
Schmidt, Fabian

Weisblum, Yiska

Jha, Divya

Tankelevich, Michael

Martinez-Delgado, Gustavo

Yee, Jim http://orcid.org/0000-0003-1595-6585
Patel, Roshni

Dizon, Juan

Unson-O’Brien, Cecille

Shimeliovich, Irina

Robbiani, Davide F. http://orcid.org/0000-0001-7379-3484
Zhao, Zhen

Gazumyan, Anna

Schwartz, Robert E. http://orcid.org/0000-0002-5417-5995
Hatziioannou, Theodora

Bjorkman, Pamela J. http://orcid.org/0000-0002-2277-3990
Mehandru, Saurabh http://orcid.org/0000-0001-9781-2969
Bieniasz, Paul D. http://orcid.org/0000-0002-2368-3719
Caskey, Marina http://orcid.org/0000-0003-1727-8693
Nussenzweig, Michel C. http://orcid.org/0000-0003-0592-8564
License Information

Text and Data Mining valid from 2021-01-18

Version of Record valid from 2021-01-18
More Information

Article History

Received: 3 November 2020

Accepted: 6 January 2021

First Online: 18 January 2021

Competing interests

: The Rockefeller University has filed a provisional patent application in connection with this work on which D.F.R. and M.C.N. are inventors (US patent 63/021,387). R.E.S. is on the scientific advisory board of Miromatrix Inc and is a consultant and speaker for Alnylam Inc. S.M. has served as a consultant for Takeda Pharmaceuticals, Morphic and Glaxo Smith Kline. Z.Z. received seed instruments and sponsored travel from ET Healthcare.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below